-
Article
Open AccessTargeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models
Resistance to therapy remains a major obstacle in cancer management. Although treatment with hormone and CDK4/6 inhibitors is successful in luminal breast cancer, resistance to these treatments is frequent, hi...
-
Article
Open AccessAuthor Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
-
Article
Open AccessHigh p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor activity than endocrine therapy alone for the treatment of advanced estrogen receptor-positive breast cancer. Some of these ...
-
Article
Open AccessA high-throughput drug screen reveals means to differentiate triple-negative breast cancer
Plasticity delineates cancer subtypes with more or less favourable outcomes. In breast cancer, the subtype triple-negative lacks expression of major differentiation markers, e.g., estrogen receptor α (ERα), an...
-
Article
Open AccessPersonalized cancer therapy prioritization based on driver alteration co-occurrence patterns
Identification of actionable genomic vulnerabilities is key to precision oncology. Utilizing a large-scale drug screening in patient-derived xenografts, we uncover driver gene alteration connections, derive dr...
-
Article
Publisher Correction: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer
In the version of this Article originally published, the boxes framing the two plots in Fig. 1g were misaligned from the axes due to a technical error. This has now been corrected in all versions of the Article.
-
Article
MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer
For many patients with breast cancer, symptomatic bone metastases appear after years of latency. How micrometastatic lesions remain dormant and undetectable before initiating colonization is unclear. Here, we ...
-
Article
Open AccessModulation of telomere protection by the PI3K/AKT pathway
Telomeres and the insulin/PI3K pathway are considered hallmarks of aging and cancer. Here, we describe a role for PI3K/AKT in the regulation of TRF1, an essential component of the shelterin complex. PI3K and A...
-
Article
Evidence for a link between TNFRSF11A and risk of breast cancer
Intracellular signaling mediated by the receptor activator of nuclear factor-κB [Rank, encoded by the tumor necrosis factor receptor superfamily, member 11a (Tnfrsf11a) gene] is fundamental for mammary gland deve...
